Alnylam Presents New Phase II, Preclinical Data from TTR Amyloidosis Programs | GenomeWeb

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week unveiled new Phase II data on its transthyretin-mediated amyloidosis (ATTR) therapy patisiran, which showed that the drug is capable of knocking down its disease-causing protein target by about 80 percent in patients — in line with previous clinical findings.

Release of the findings come as the company moves ahead with a recently initiated Phase III trial of patisiran in patients with a manifestation of ATTR known as familial amyloidotic polyneuropathy that is characterized by damage to the peripheral nervous system.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

This Week in Science: New research into the emergence of infectious diseases, and scientists report on proteins involved in melanoma.

The hashtag #stupidcommonnames is gaining fans among scientists who find the common names of some animals and plants dumb.

Fed up with budget slashes, job cuts, and muzzling mandates, researchers in Canada are making science a campaign issue in the upcoming elections.

A former NIH program officer says the Internet has blasted open the door for scientific publications more interested in dollars than quality research.

Sep
10
Sponsored by
Qiagen

In this online seminar, Jo Vandesompele of the Center for Medical Genetics at Ghent University will discuss methods for improving the analysis of microRNA expression from a range of samples.